welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Hope in Translation: Bringing Gene Therapy to the Clinic
In 1987, scientists first uncovered the gene that is the target of mutations that causes Duchenne muscular dystrophy (DMD), a lethal muscle-wasting disease that affects about one in every 5,000 newborn boys. While the discovery of the dystrophin gene sparked hope that scientists could someday replace the mutated gene with a healthy one, turning this concept into a safe and effective treatment has been a decades-long challenge.
In drug discovery, the process of converting early biological insights into a therapy that can be tested in the clinic is known as translational research. It’s rigorous and very often painstaking work that happens behind the scenes, but the nonetheless is a critical bridge to bringing life-transforming treatments to patients. And in the journey of developing a gene therapy for DMD, scientists have had to overcome significant hurdles due to the complexity of the disease and the various challenges of engineering vector delivery systems.

rareRelated
-
Crispr Halted Muscular Dystrophy In Dogs. Someday, It Might Cure Humans.Today, our partner Dr. Eric Olson and hi...
-
George Dickson, PhDGeorge Dickson is Emeritus Professor of ...
-
Development of Novel Micro-dystrophins with Enhanced FunctionalityGene therapies using adeno-associated vi...
-
AAV-Based Gene Therapies for the Muscular DystrophiesMuscular dystrophy is a group of progres...
-
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Inc., a life sciences ...
-
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
-
NIH Awards $86 Million to Improve Genome Editing TechniquesSomatic Cell Genome Editing support is a...